Home CompaniesBayer Bayer to Sell Men’s Health Product Nebido™ to Grünenthal for 500 Million Euro.

Bayer to Sell Men’s Health Product Nebido™ to Grünenthal for 500 Million Euro.

by admin
0 comment

Summary : Bayer and Grünenthal have entered into a definitive agreement regarding the sale of Bayer’s men’s health product Nebido™ (testosterone undecanoate), for a purchase price totaling up to 500 million Euro.

Nebido for the treatment of male hypogonadism (testosterone deficiency) is available in over 80 countries since 2004. In 2021, the product contributed sales of 117 million Euro to Bayer’s overall sales of more than 44 billion Euro.

“This divestment is part of the ongoing transformation of our pharmaceuticals business, which focuses on key areas of healthcare innovation,” said Marianne De Backer, PhD, MBA, Member of the Executive Committee and EVP, Head Strategy and Business Development & Licensing and Open Innovation, Pharmaceuticals Division of Bayer AG. “Its proceeds will support investments in future innovation and bring forward transformative treatment options for patients.”


Bayer to Sell Men’s Health Product Nebido™ to Grünenthal for 500 Million Euro.

About Nebido™ (Testosterone undecanoate depot injection)

  • Description -Testosterone undecanoate, sold under the brand names Andriol and Aveed among others, is an androgen and anabolic steroid medication that is used mainly in the treatment of low testosterone levels in men, including hormone therapy for transgender men. It is taken by mouth or given by injection into muscle.
  • Class- Anabolic steroids; Androstenols; Hormonal replacements; Small molecules; Testosterone congeners
  • Mechanism of Action- Testosterone replacements
  • Indication – Hypogonadism
  • Orphan Drug Status- No

Grünenthal will acquire the global product rights to Nebido™ for an upfront purchase price of up to 500 million Euro, subject to customary closing adjustments, including the contract business in the U.S, where Endo Pharmaceuticals has licensed the compound under the name Aveed from Bayer. The transaction is expected to close by the end of 2022, pending the satisfaction of customary closing conditions, including approval by the competition authorities.

UBS Investment Bank acted as financial advisor to Bayer, while Allen & Overy provided legal advice.

About Bayer

Bayer is a global enterprise with core competencies in the life science fields of health care and nutrition. Its products and services are designed to help people and the planet thrive by supporting efforts to master the major challenges presented by a growing and aging global population. Bayer is committed to driving sustainable development and generating a positive impact with its businesses. At the same time, the Group aims to increase its earning power and create value through innovation and growth

    Weblink: https://www.chemrobotics.com

    • AgroPat Lite– Access 5500 pesticides with chemistry, Biology, Regulatory, and IP info. Covers the product information including formulation, combination, developer, innovator, existing intellectual property, regulatory requirement, biology data including spectrum, MOA, DFU, toxicity profile, and safety. (Designed for Business Development function)

    You may also like

    Leave a Comment

    This site uses Akismet to reduce spam. Learn how your comment data is processed.

    Our Company

    ChemRobotics is a global Scientific, Technical & Business data intelligence company, especially in the field of Pharmaceutical, Agrochemical, Veterinary and Fine Chemical.

    ChemRobotics Times

    Subscribe ChemRobotics for the latest updates in the Pharmaceutical, Agrochemical, Veterinary, and Fine Chemical Industries

    Laest News

    ChemRobotics Pvt. Ltd. © 2023, All Rights Reserved. 

    Designed and Developed by Ample eBusiness